216 related articles for article (PubMed ID: 28953573)
1. Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder.
Liberman D; Milhouse O; Johnson-Mitchell M; Siegel SW
Female Pelvic Med Reconstr Surg; 2018; 24(6):404-407. PubMed ID: 28953573
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
3. Prolonged urinary retention after intravesical botulinum injection for treatment of idiopathic detrusor overactivity.
King AB; Rapp DE
Can J Urol; 2011 Apr; 18(2):5657-9. PubMed ID: 21504656
[TBL] [Abstract][Full Text] [Related]
4. What is the true catheterization rate after intravesical onabotulinumtoxinA injection?
Patel DN; Jamnagerwalla J; Houman J; Anger JT; Eilber KS
Int Urogynecol J; 2018 Jul; 29(7):1005-1009. PubMed ID: 28808734
[TBL] [Abstract][Full Text] [Related]
5. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
6. The Correlation of Diabetes Mellitus and Urinary Retention From Intravesical OnabotulinumtoxinA Injection for Overactive Bladder.
Takashima Y; Handler S; Laus K; Eckhardt S; Whitaker T; Tenggardjaja C; Yazdany T
Urogynecology (Phila); 2023 May; 29(5):511-519. PubMed ID: 36730351
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity.
Liao CH; Kuo HC
J Urol; 2013 May; 189(5):1804-10. PubMed ID: 23178902
[TBL] [Abstract][Full Text] [Related]
8. Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings.
Kennelly M; Green L; Alvandi N; Wehbe S; Smith JJ; MacDiarmid S; Mangel J; Schwartz M; Aboushwareb T; Murray B
Curr Med Res Opin; 2018 Oct; 34(10):1771-1776. PubMed ID: 29458265
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin treatment for overactive bladder: risk of urinary retention.
Shaban AM; Drake MJ
Curr Urol Rep; 2008 Nov; 9(6):445-51. PubMed ID: 18947508
[TBL] [Abstract][Full Text] [Related]
10. Long-term compliance and results of intravesical botulinum toxin A injections in male patients.
Rahnama'i MS; Marcelissen TAT; Brierley B; Schurch B; de Vries P
Neurourol Urodyn; 2017 Sep; 36(7):1855-1859. PubMed ID: 28084637
[TBL] [Abstract][Full Text] [Related]
11. Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?
Kuo YC; Kuo HC
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26999201
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
13. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study.
Kuo HC; Liu HT; Chuang YC; Birder LA; Chancellor MB
Eur Urol; 2014 Jun; 65(6):1117-24. PubMed ID: 24555904
[TBL] [Abstract][Full Text] [Related]
15. Onabotulinum toxin A Injections in Men With Refractory Idiopathic Detrusor Overactivity.
Faure Walker NA; Syed O; Malde S; Taylor C; Sahai A
Urology; 2019 Jan; 123():242-246. PubMed ID: 30266377
[TBL] [Abstract][Full Text] [Related]
16. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
17. Single-centre experience with intradetrusor injection of onabotulinumtoxinA: a retrospective study of the years 2003-2012 in a Danish population.
Christiansen FE; Pedersen TB; Juel J; Kirkeby HJ
Scand J Urol; 2017 Oct; 51(5):392-396. PubMed ID: 28699369
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
[TBL] [Abstract][Full Text] [Related]
19. Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery.
Liao CH; Wang CC; Jiang YH
Toxins (Basel); 2016 Mar; 8(4):91. PubMed ID: 27023603
[TBL] [Abstract][Full Text] [Related]
20. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.
Krhut J; Zvara P
Int Urol Nephrol; 2011 Jun; 43(2):337-43. PubMed ID: 20563845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
